Appendix 4D Financial Report for half-year to 30th June 2019
Telix Pharmaceuticals Limited is pleased to provide appendix 4D half-year report for the six months ended 30th June...
Read more
Latest News
Category: ASX
Telix Pharmaceuticals Limited is pleased to provide appendix 4D half-year report for the six months ended 30th June...
Read more
Telix Pharmaceuticals Ltd is pleased to announce Appendix 3B – Issue of shares under Share Purchase Plan...
Read more
Telix Pharmaceuticals Limited is pleased to advise that, at closing on Friday 16th August 2019, subscriptions under the Company’s Share Purchase Plan (“SPP”) totaled approximately $9.6...
Read more
Telix Pharmaceuticals Limited is pleased to provide its Annual Report...
Read more
Telix Pharmaceuticals Limited is pleased to provide a detailed Program Update January...
Read more
Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised...
Read more
Telix Pharmaceuticals Limited is pleased to announce the opening of its Initial Public Offering to raise A$50...
Read more
Telix Pharmaceuticals is pleased to announce it has filed a $50 million Underwritten Initial Public...
Read more
Telix is pleased to announce the conclusion of collaboration and licensing agreement with CellSight Technologies, Inc. (CellSight) for the VisAcT immunoPET imaging technology...
Read more
Telix is pleased to announce the completion of a Master Services Agreement with Cyclotek (Aust) Pty Ltd...
Read more